The influence of lymphoid enhancer binding factor-1 expression on the outcome of adult acute promyelocytic leukemia patients.

IF 2.3 4区医学 Q2 HEMATOLOGY

Expert Review of Hematology Pub Date : 2025-02-23 DOI:10.1080/17474086.2025.2467870

Thoraya M Abdelhamid, Yasmine Y Hassaneen, Mohamed Ghareeb, Eman O Rasekh

{"title":"The influence of lymphoid enhancer binding factor-1 expression on the outcome of adult acute promyelocytic leukemia patients.","authors":"Thoraya M Abdelhamid, Yasmine Y Hassaneen, Mohamed Ghareeb, Eman O Rasekh","doi":"10.1080/17474086.2025.2467870","DOIUrl":null,"url":null,"abstract":"Background: Acute promyelocytic leukemia (APL) is considered one of the greatest success stories in cancer therapy. However, early deaths remain the leading cause of treatment failure. This study aimed to analyze LEF1 expression in adult APL patients to evaluate its impact on survival outcomes, particularly early deaths.Research design and methods: LEF1 expression was analyzed by RT-qPCR in 78 denovo adult APL samples and 20 bone marrow samples from healthy matched donors as a control group. The cutoff for LEF1 fold change was set at 0.2250 using the receiver operating characteristic curve.Results: LEF1 expression was down regulated in APL patients as compared to the control group with statistically significant difference between the two groups (p < 0.001). The incidence of early deaths was higher in the low-LEF1 expressers than in high expressers (p = 0.018). LEF1 was determined to be an independent factor affecting early deaths. The high-risk patient group with low LEF1 expression had the worst overall survival.Conclusions: This study supports the potential of LEF1 to be a prognostic parameter in APL and a predictor of early deaths. Incorporating LEF1 into risk stratification could help to minimize early deaths. Future studies should explore combined risk factor analyses for improved prognosis in APL patients.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"1-9"},"PeriodicalIF":2.3000,"publicationDate":"2025-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17474086.2025.2467870","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Acute promyelocytic leukemia (APL) is considered one of the greatest success stories in cancer therapy. However, early deaths remain the leading cause of treatment failure. This study aimed to analyze LEF1 expression in adult APL patients to evaluate its impact on survival outcomes, particularly early deaths.

Research design and methods: LEF1 expression was analyzed by RT-qPCR in 78 denovo adult APL samples and 20 bone marrow samples from healthy matched donors as a control group. The cutoff for LEF1 fold change was set at 0.2250 using the receiver operating characteristic curve.

Results: LEF1 expression was down regulated in APL patients as compared to the control group with statistically significant difference between the two groups (p < 0.001). The incidence of early deaths was higher in the low-LEF1 expressers than in high expressers (p = 0.018). LEF1 was determined to be an independent factor affecting early deaths. The high-risk patient group with low LEF1 expression had the worst overall survival.

Conclusions: This study supports the potential of LEF1 to be a prognostic parameter in APL and a predictor of early deaths. Incorporating LEF1 into risk stratification could help to minimize early deaths. Future studies should explore combined risk factor analyses for improved prognosis in APL patients.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Hematology HEMATOLOGY-

CiteScore

4.70

自引率

3.60%

发文量

审稿时长

6-12 weeks

期刊介绍： Advanced molecular research techniques have transformed hematology in recent years. With improved understanding of hematologic diseases, we now have the opportunity to research and evaluate new biological therapies, new drugs and drug combinations, new treatment schedules and novel approaches including stem cell transplantation. We can also expect proteomics, molecular genetics and biomarker research to facilitate new diagnostic approaches and the identification of appropriate therapies. Further advances in our knowledge regarding the formation and function of blood cells and blood-forming tissues should ensue, and it will be a major challenge for hematologists to adopt these new paradigms and develop integrated strategies to define the best possible patient care. Expert Review of Hematology (1747-4086) puts these advances in context and explores how they will translate directly into clinical practice.